ABSTRACT Aldosterone and cortisol, the main mineralocorticoid and glucocorticoid hormones in humans, are produced in the adrenal cortex, which is composed of three concentric zones with specific functional characteristics. Adrenocortical adenomas (ACAs) can lead to the autonomous secretion of aldosterone responsible for primary aldosteronism, the most frequent form of secondary arterial hypertension. In the case of cortisol production, ACAs lead to overt or subclinical Cushing syndrome. Genetic analysis driven by next-generation sequencing technology has enabled the discovery, during the past 7 years, of the genetic causes of a large subset of ACAs. In particular, somatic mutations in genes regulating intracellular ionic homeostasis and membrane potential have been identified in aldosterone-producing adenomas. These mutations all promote increased intracellular calcium concentrations, with activation of calcium signaling, the main trigger for aldosterone production. In cortisol-producing adenomas, recurrent somatic mutations in PRKACA (coding for the cyclic adenosine monophosphatedependent protein kinase catalytic subunit a) affect cyclic adenosine monophosphate-dependent protein kinase A signaling, leading to activation of cortisol biosynthesis. In addition to these specific pathways, the Wnt/b-catenin pathway appears to play an important role in adrenal tumorigenesis, because b-catenin mutations have been identified in both aldosterone-and cortisol-producing adenomas. This, together with different intermediate states of aldosterone and cortisol cosecretion, raises the possibility that the two conditions share a certain degree of genetic susceptibility. Alternatively, different hits might be responsible for the diseases, with one hit leading to adrenocortical cell proliferation and nodule formation and the second specifying the hormonal secretory pattern. (Endocrine Reviews 38: 516 -537, 2017) 
A drenal masses are quite common, being found in~% of the general population, with the prevalence increasing with age (). Functional adrenocortical adenomas are a group of benign tumors of the adrenal cortex autonomously secreting excess hormones. Aldosterone-producing adenomas (APAs) are responsible for primary aldosteronism (PA), the most frequent form of secondary hypertension. Cortisol-producing adenomas (CPAs) are responsible for overt Cushing syndrome (CS) or subclinical Cushing syndrome (sCS). In addition, both diseases can also result from different forms of adrenal hyperplasia: bilateral adrenal hyperplasia (BAH) in PA and primary bilateral macronodular adrenal hyperplasia (PBMAH) responsible for overt CS or sCS. Primary pigmented nodular adrenal hyperplasia is a rare condition responsible for overt CS. Unilateral adrenal hyperplasia leading to autonomous aldosterone or cortisol production has also been described. In between the two conditions are histological forms of multinodular adrenal glands in which hormone production can be localized to one large nodule or to multiple nodules. Sometimes cosecretion of aldosterone and cortisol is observed in one adrenal gland, either from one adenoma or from distinct adenomas. the expression of specific steroidogenic enzymes and the ability to respond to unique regulatory stimuli. In particular, the outer zona glomerulosa (ZG) produces aldosterone through the activity of aldosterone synthase (encoded by CYPB), which catalyzes the three terminal reactions of aldosterone biosynthesis: hydroxylation at position C of the steroid intermediate deoxycorticosterone, yielding corticosterone, followed by hydroxylation at position C, yielding -hydroxy-corticosterone, and a subsequent oxidation of the hydroxyl group at C, which results in the formation of aldosterone. Cortisol biosynthesis occurs in the zona fasciculata (ZF), where the expression of a hydroxylase mediates conversion of -deoxy--carbon steroids into -hydroxy--carbon steroids, precursors of cortisol. Because a hydroxylase is not expressed in rats and mice, the main glucocorticoid in these species is corticosterone (). Cortisol is synthesized from OH-progesterone through -hydroxylation to form -deoxycortisol, followed by hydroxylation at position C by b-hydroxylase (encoded by CYPB). The two highly homologous genes CYPB and CYPB are located in tandem on human chromosome q-. Unequal crossing over of the two genes during meiosis results in a chimeric gene composed of the regulatory regions of CYPB fused to the coding sequence of CYPB, which is responsible for familial hyperaldosteronism (FH) type  (also known as glucocorticoid remediable aldosteronism) (). Under these conditions, aldosterone synthase expression and aldosterone biosynthesis are regulated by adrenocorticotropic hormone (ACTH) in the ZF of the adrenal cortex, rather than by angiotensin II (AngII), with a circadian rhythmicity of aldosterone production following that of cortisol () and production of the hybrid steroids -hydroxycortisol and -oxocortisol (, ).
The main regulators of aldosterone biosynthesis are the renin-angiotensin system, the concentration of extracellular potassium, and ACTH (). The reninangiotensin system translates changes in renal perfusion or sodium concentration sensed by the distal tubule into changes in aldosterone production from the adrenal cortex to maintain volume and electrolyte homeostasis. AngII acts via the AT receptor expressed in ZG cells, activating a Gaq-phospholipase C-mediated pathway, leading to increased inositol ,,-triphosphhate (IP) and ,-diacylglycerol concentrations. IP increases intracellular calcium concentrations by calcium release from intracellular stores.
AngII also inhibits the background potassium channel TASK (TWIK-related acid-sensitive potassium channel) and the Na + ,K + -adenosine triphosphatase (ATPase), leading to cell membrane depolarization and activation of voltage-gated Ca + channels, again increasing intracellular calcium concentrations. Extracellular potassium is the other major regulator of aldosterone production, exerting a large amplitude of control over a wide range of potassium concentrations. This is possible because the main ionic conductance of ZG cells is that of K + and the cell membrane potential closely follows the equilibrium potential of K + over a large range of extracellular K + concentrations (). Elevation of the extracellular K + concentration, a decrease in the intracellular K + concentration, inhibition of Na + ,K + -ATPase, or closure of potassium channels all lead to cell membrane depolarization, opening of voltage-dependent Ca + channels, and an increase in intracellular calcium concentrations, resulting in activation of calcium signaling.
Increased calcium signaling affects aldosterone production in several methods. Calcium signaling increases activity of cholesterol ester hydrolase with subsequent release of deesterified cholesterol from cytoplasmic stores, promotes cholesterol delivery to the outer mitochondrial membrane and its transfer to the inner mitochondrial membrane by increasing expression of the steroid acute regulatory protein (StAR), and increases the synthesis of cofactors required for p cytochrome enzymes (). Stimulation of CYPB transcription is mediated by calcium/ calmodulin binding and activation of protein kinases regulating phosphorylation of several transcription factors, in particular, nuclear receptor subfamily  group A members  and  (NURR or NGFB and NURR), the cyclic adenosine monophosphate (cAMP)-dependent transcription factor ATF- and the cAMP-responsive element-binding protein () [ Fig. (A) ].
Cortisol production is regulated by the hypothalamus-pituitary-adrenal axis, whereby circadian input and stress stimuli induce release of cortisol via corticotrophin releasing hormone-dependent ACTH secretion, and cortisol signals back to exert negative feedback on the hypothalamus and the pituitary. In the ZF (and zona reticularis) of the adrenal cortex, ACTH binds to its receptor MCR (melanocortin receptor ), which signals through Gas-mediated signaling to increase intracellular cAMP levels and activate protein kinase A (PKA) [ Fig. (B) ] (). Acute stimulation by ACTH elicits effects on steroidogenesis by regulating cholesterol availability, mobilizing cholesterol from lipid stores, and increasing cholesterol transport into mitochondria and by stimulating transcription of steroidogenic genes. Rapid effects occurring within minutes mainly affect StAR activity through phosphorylation, and longer stimulation (days) by ACTH results in transcriptional regulation of StAR and steroidogenic enzymes. In particular, PKA signaling activates transcription factors regulating expression of steroidogenic genes, including steroidogenic factor , cAMP-responsive elementbinding protein, cAMP responsive element modulator, CCAAT/enhancer-binding proteins, and activator protein  (). ACTH also regulates aldosterone production acutely via cAMP-mediated pathways; however, chronically, ACTH also suppresses plasma aldosterone in both human and animal models and downregulates CYPB, inducing CYPB expression and promoting a ZF phenotype (, ). Long-term exposure to ACTH (weeks or months) stimulates adrenal growth and promotes adrenal cell hypertrophy and hyperplasia. In extreme cases of glucocorticoid deficiency or ACTH excess and in experimental models of corticotrophin releasing hormone or ACTH deficient mice, the trophic effects of the hormone lead to major hyperplasia or atrophy, respectively, of the inner zones of the adrenal cortex (). In addition to acting through cAMP, ACTH stimulates calcium influx in glomerulosa cells by activation of L-type Ca + channels (). Many other factors have been shown to modulate aldosterone and cortisol production, including neurotransmitters, cytokines, vascular products, and adipokines, as well as locally produced ACTH acting through a paracrine mechanism (, ). concentrations and, thus, aldosterone biosynthesis. (B) Specific mechanisms of CPA formation. In the absence of stimulation, the catalytic and regulatory subunits of PKA form an inactive complex. Binding of ACTH to its receptor, the melanocortin 2 receptor (MC2R), leads to activation of adenylate cyclase, resulting in an increase in cAMP. cAMP binds to the regulatory subunits of the PKA complex, inducing conformational changes and release of the catalytic subunits from the complex. Active PKA phosphorylates specific target proteins such as the transcription factor cAMP-responsive element-binding protein (CREB) that binds to the promoter regions of specific target genes (i.e., CYP11B1), leading to increased cortisol biosynthesis. In cells, cAMP is converted into AMP through the action of specific phosphodiesterase. Mutations in PRKACA or GNAS lead to the constitutive activation of PKA, phosphorylation of CREB, and increased expression of CYP11B1 and autonomous cortisol biosynthesis. (C) Common mechanisms of APA and CPA formation. In unstimulated cells, b-catenin is phosphorylated, ubiquitinated by a protein complex formed by APC, GSK3, axin, and CK1a and then degraded by the proteasome. Binding of Wnt ligand to the frizzled receptor and LRP5/6 coreceptor leads to the dissociation of the b-catenin degradation complex. b-Catenin can translocate into the nucleus, where it acts as a transcriptional coactivator for transcription factors of the TCF/LEF family, inducing the expression of specific target genes. In APAs and CPAs, CTNNB1 mutations affecting specific residues of b-catenin lead to constitutive activation of the protein. In APAs, mutations in APC also lead to constitutive b-catenin activation. Color codes indicate the involved pathway. 
Somatic Mutations in APA
PA is due to autonomous aldosterone production from the adrenal cortex and is diagnosed on the basis of hyperaldosteronism associated with suppressed renin and, often, hypokalemia (). It is the most common form of secondary hypertension, with a prevalence of % to % in patients with arterial hypertension (, ) and #% in patients with resistant hypertension (). PA is associated with increased cardiovascular risk, in particular, coronary artery disease, nonfatal myocardial infarction, heart failure, atrial fibrillation, renal damage, and stroke (-), due to the blood pressureindependent effects of aldosterone on cardiac and vascular remodeling (, ).
Most cases of PA are due to APA or BAH (also called idiopathic hyperaldosteronism). Only in rare cases has unilateral adrenal hyperplasia been described, and aldosterone-producing adrenocortical cancers are extremely rare. APAs are generally small (, cm in diameter) and are diagnosed by adrenal computed tomography and adrenal venous sampling, which identifies lateralized aldosterone secretion in the presence or absence of a visible adrenal nodule on imaging (, ). Recent advances in genome technology have allowed for the identification, during the past  years, of several somatic mutations in APAs, providing a pathogenic model for PA development. Whole exome sequencing (WES) of paired tumor (somatic) and germline DNA performed by different groups on . APA samples identified recurrent somatic mutations in genes coding for ion channels [KCNJ () and CACNAD (, )] and ATPases [ATPA and ATPB (, )] regulating intracellular ionic homeostasis and cell membrane potential, thus defining APA as a channelopathy. These mutations all promote increased intracellular calcium concentrations, leading to activation of calcium signaling, the main trigger for aldosterone biosynthesis (Fig. ) . A small fraction of APAs also carries somatic mutations in CTNNB, coding for b-catenin, similar to CPA (see subsequent sections) and adrenocortical cancer (, ) ( Table ) . In the largest multicenter study reported, exploring the prevalence of somatic mutations in KCNJ, CACNAD, ATPA, and ATPB in  patients from seven centers belonging to the European Network for the Study of Adrenal Tumors, somatic mutations were detected in % of APAs, ranging from .% to .% across the different centers (). In that study, KCNJ mutations were the most prevalent genetic abnormality and were found in % of APAs. Mutations affecting CACNAD were the second most prevalent genetic abnormalities, present in .% of cases, and ATPA and ATPB mutations were identified in .% and .% of cases, respectively. No difference was found in cellular composition (percentage of cells resembling ZF or ZG) of APAs or in CYPB, KCNJ, CACNAD, or ATPA gene expression in APAs across genotypes. Patients with KCNJ mutations were more frequently female and younger at diagnosis and had greater plasma potassium concentrations compared with CACNAD mutation carriers or noncarriers. CACNAD mutations were associated with smaller adenomas. No association was found between the mutation status and preoperative plasma aldosterone or renin levels, the aldosterone/renin ratio, or the number of medications taken before surgery. Also, no association was found with postoperative blood pressure outcomes, treatment scores during follow-up, or cure or improvement of hypertension. These associations were largely center-dependent, which might have resulted from the heterogeneity of APAs, which should also be considered when studying genotypephenotype correlations ().
Furthermore, less frequent mutations have been identified in a few genes in patients with peculiar phenotypes of PA, including early-onset PA and tumors cosecreting aldosterone and cortisol (, ) ( Table ) Pathogenic mechanisms of APA development KCNJ codes for the G protein-activated inward rectifier potassium channel GIRK (alternative protein name Kir.), which is composed of two membranespanning domains (M and M), one pore-forming region (H), and cytoplasmic N-and C-termini that contribute to the pore structure. Recurrent somatic mutations identified in APAs cluster within or near the selectivity filter of the channel pore, between amino acids Thr and Gly (Table ) . They affect its ionic selectivity, rendering the channel permeable to sodium, with increased sodium influx into the cell leading to chronic cell membrane depolarization and opening of voltage-gated calcium channels (). This, in turn, leads to increased intracellular calcium concentrations and activation of calcium signaling [ Fig.  (A) ]. Transient transfection of KCNJ mutants into adrenocortical cells increases aldosterone production and expression of CYPB in a calcium-dependent manner (); in some cases, mutations lead to reduced membrane and total abundance of GIRK (). Transiently transfected KCNJ mutants did not lead to enhanced cell proliferation ex vivo but, rather, to reduced cell viability or sodium-dependent cell death, which does not explain the cell proliferation and APA formation (, ). Whether these findings resulted from experimental artifacts caused by high expression of transfected channels, leading to excessively increased sodium influx into the cell, which does not reflect the in vivo situation, or whether additional hits are required for cell proliferation, remains a matter of debate.
CACNAD codes for the a subunit of the L-type voltage-gated Cav. calcium channel (calcium channel, voltage-dependent, L type, a-d subunit), and ATPA codes for the a subunit of the Na (Table ) . They lead to a loss of pump activity and a reduced affinity for K + and to an inward proton or sodium leak, which has been proposed to increase aldosterone production through cell membrane depolarization and increased calcium influx, which has been observed in the presence of KCNJ mutations (, ). However, transient transfections of Na Finally, CACNAD mutations affect the function of the L-type Ca + channel a-subunit Cav., which is composed of four repeat domains (I to IV), each consisting of six transmembrane segments S to S, with a membrane-associated loop between S and S ( Table  Genotype-phenotype correlations in APA KCNJ mutations are the most frequent type of somatic mutation within APAs (Table ) . Their reported frequency ranges from % to %, with greater frequency in studies from Japan, China, Korea, and Taiwan (-, ). CACNAD mutations are the second most frequent mutations (#%), followed by ATPA and ATPB. Three studies have also explored CTNNB mutations, which are found in .% to .% of cases (, , ).
The correlations of clinical and molecular parameters with the mutation status have been heterogeneous among studies (Table ) . In a recent meta-analysis, Lenzini et al. () analyzed the clinical correlates of KCNJ mutations in  patients from  studies. The overall prevalence of KCNJ mutations was %, ranging from % to % among different studies, with a greater prevalence in studies from Japan and China compared with studies of populations from Europe, the United States, and Australia. The carriers of KCNJ mutations were younger, were more often female, had larger tumors, and had higher plasma aldosterone levels compared with noncarriers. No association was observed between the mutation status and systolic or diastolic blood pressure and serum potassium levels overall, confirming previous results from the study by Fernandes-Rosa et al. () . An association between the presence of KCNJ mutations and the lateralization index at adrenal vein sampling was described in two studies (, ) but was not replicated in another study (). In four studies, KCNJ mutations were associated with tumors composed mainly of large, lipid-laden cells resembling ZF cells ( Table ) . The other mutations were associated mainly with male sex and smaller tumors (-, , , ), and the cellular phenotype of APA carrying CACNAD, ATPA, or ATPB mutations was more heterogeneous than the cellular phenotype of KCNJ-mutated tumors. Although few studies have investigated CTNNB mutations in large cohorts, they seem to be more prevalent in females (, , , ).
Germline mutations in APA
In addition to somatic mutations, the occurrence of germline CACNAH (coding for the voltagedependent T-type calcium channel subunit a-H) mutations, and, rarely, germline KCNJ and ARMC variants have been reported in PAs (, , ). Daniil et al. () performed WES in patients with different phenotypic presentations of PA, including  patients with APA,  patients with a family history of PA, and  patient with early-onset PA. CACNAH mutations were identified in the patient with early-onset PA and the patients with a family history, and a germline CACNAH p.ValGlu mutation was identified in one patient with an APA (). CACNAH encodes the pore-forming a subunit of the T-type voltagedependent calcium channel Cav., which has been implicated in membrane potential oscillations in ZG cells (). The variant is located in the C-terminal cytoplasmic domain of Cav., in a region possibly implicated in fast channel activation. Electrophysiological investigation revealed a gain-of-function phenotype, whereby p.ValGlu induced a faster recovery from inactivation and marked increase in voltage-dependent facilitation, two properties which could favor larger calcium entry during repetitive electrical activity. In HR adrenocortical cells, transient transfection of the mutant channel led to an increase in aldosterone biosynthesis and expression of CYPB ().
Genetic abnormalities in APA driver genes are present as germline mutations in some familial forms of PA, which account for % to % of cases and are transmitted as an autosomal dominant trait. Although the terminology for FH is still evolving, to date, four different forms of FH, FH-I to FH-IV, have been described. FH-I, resulting from the formation of a chimeric gene between CYPB and CYPB (see the preceding sections), is found in .% to .% of cases of PA (-) but might represent #% of cases in the pediatric hypertensive population (). FH-I is associated with BAH; however, in rare cases, adrenocortical adenomas have been described. Heterozygous germline mutations in KCNJ are found in FH-III, a severe form of PA presenting, in typical cases, in childhood with severe hypertension and profound hypokalemia, due to massive BAH, which requires bilateral adrenalectomy to control the hypertension (). In other cases, the disease will be milder and with normal-appearing adrenals on imaging studies (). Germline mutations in CACNAH have recently been identified as the cause of a new form of early-onset PA associated or not with a developmental disorder (, ). In familial cases, the disease (termed FH-IV) is transmitted as an autosomal dominant trait. Similar mutations have also been found in patients with a diagnosis of FH-II, with or without an adrenal adenoma, and in those with APAs (). Finally, de novo germline CACNAD mutations have been described in a rare disease termed PASNA (primary aldosteronism, seizures, neurologic abnormalities), with no adrenal abnormality reported on imaging studies ().
Pathological and Genetic Heterogeneity and the Origin of APA
Although the functional link between mutations in driver genes in APA and aldosterone production has been clearly demonstrated, the origin of APA in terms of increased cell proliferation and nodule formation is not yet well understood. However, work from different groups has provided contradictory results on the sequence of events leading to aldosterone overproduction and adenoma formation. Familial forms of PA are due to germline mutations in driver genes, supporting a role for these mutations in adrenal cortex cell proliferation and nodulation. However, adrenal morphology is highly variable among these subjects. Patients with FH-III harboring germline KCNJ mutations can exhibit adrenal phenotypes ranging from a normal adrenal gland to massive BAH or adrenal nodules (, , ). Similarly, patients carrying germline CACNAH mutations show different adrenal phenotypes, including normal, hyperplastic, and adenomatous adrenal glands (, ). No abnormality in adrenal morphology was observed in patients with PASNA harboring germline CACNAD mutations (). Ex vivo, adrenocortical cells overexpressing mutant GIRK channels show increased intracellular Na + concentrations, leading, counterintuitively, to reduced cell proliferation and sodiumdependent apoptosis (, ).
It has been previously shown that adrenal glands with APA exhibit adrenal cortex remodeling, decreased vascularization, increased nodulation, and ZG hyperplasia (, ). These findings suggest that adrenal cortex remodeling might precede APA development and that the somatic mutations in driver genes are secondary events specifying the pattern of hormone secretion. The recent development of an aldosterone-synthase antibody () has allowed for assessment of the genetic and histological characteristics of adrenal glands with APA and reinforced the hypothesis of independent events leading to nodulation and aldosterone overproduction. Two studies in particular have identified different genetic abnormalities in different aldosterone-producing nodules from the same adrenal gland. In one study, Dekkers et al. () analyzed  multinodular adrenal glands and identified  adrenal glands with more than one nodule staining positively for aldosterone synthase. In one adrenal gland, two aldosterone-synthase positive nodules each harbored a different KCNJ mutation (). In the second study, assessment of the KCNJ, ATPA, ATPB, and CACNAD mutation status in aldosterone synthase-positive nodules from  multinodular adrenals with APA identified seven adrenal glands harboring different mutations between the principal nodule and the secondary nodule within the same adrenal gland, including two adrenal glands with an APA harboring a CACNAD mutation and, in one secondary nodule, a KCNJ mutation (). Further studies extended the heterogeneity of aldosterone synthase expression to the APA itself, with KCNJ mutations only identified in APA regions positive for aldosterone synthase (). Finally, in a young patient with PA, a germline APC mutation, and a multinodular adrenal gland with somatic biallelic inactivation of APC, we identified a somatic KCNJ mutation in the nodule expressing aldosterone synthase only (see subsequent sections) (). These data support a two-hit model for APA formation whereby a specific genetic or epigenetic event is responsible for adrenal cortex remodeling and nodule formation and somatic mutations in driver genes leading to excessive aldosterone secretion represent second hits specifying the pattern of hormonal secretion (Fig. ) .
A second model for the origin of APA has emerged from genetic studies performed on aldosteroneproducing cell clusters (APCCs). APCCs, which are found in normal adult adrenal glands and adrenal glands with APAs, are composed by ZG-like cells expressing disabled homolog  (DAB; a marker of ZG) in contact with the capsule and inner columnar DAB-negative ZF-like cells, which do not express CYPB, forming cords along sinusoids (, ). APCC cells are positive for CYPB and bHSD staining but not for CYP, consistent with their capacity to synthesize aldosterone (). Targeted nextgeneration sequencing was performed on the DNA of  APCCs micro-dissected from adrenal glands from kidney transplant donors. Somatic mutations in CACNAD, ATPA, and ATPB, similar to those already described in APA, were identified in % of the "New genetic studies of a larger number of normal and pathological adrenal glands with APCCs are necessary."
APCCs (). The authors propose that APA may derive from APCC (Fig. ) and suggest different hypotheses for this progression: single somatic mutations responsible for aldosterone production and cell proliferation or second-hit mutations within the APCCs leading to cell proliferation. In some cases, APCCs might represent terminal lesions without the capacity to progress toward an adenoma (). No KCNJ mutations, the most frequent genetic alteration observed in APAs, were identified in APCCs. The investigators suggested that this could be explained by a rapid progression of KCNJ-mutated APCCs to APAs (). Subsequently, CACNAD mutations were identified in  of  APCCs from patients with lateralized PA negative for detectable masses on imaging, suggesting that these lesions might contribute to PA in this situation (). Recently, a novel aldosterone-producing structure named a possible APCC-to-APA transitional lesion (pAATL) was described in multinodular adrenal glands from two patients with lateralized PA and was suggested to be an intermediate lesion between APCCs and APAs (). Although the APCC-like portion consists of a subcapsular ZG-like region and an inner ZF-like region expressing CYPB but not CYPB, the micro-APA-like portion is composed of a heterogeneous mixture of CYPB-positive and CYPB-positive cells. Sequencing of the known APA-associated mutations in three pAATLs identified a KCNJ mutation and an ATPA mutation in the micro-APA-like portion of two pAATLs but not in their corresponding APCC-like portions. The investigators suggested that these data support the hypothesis that the microAPAs are derived from the APCCs after the appearance of an APA driver mutation (). However, another pAATL carried two novel ATPA mutations in both the micro-APA-like and APCC-like portions, supporting a clonal origin of the two portions (). New genetic studies of a larger number of normal and pathological adrenal glands with APCCs are necessary to clarify the relationship between these aldosteroneproducing lesions and the origin of APA.
Genetic Abnormalities in CPAs
The genetics of CPAs was unraveled in  by the work of four independent groups identifying somatic mutations of PRKACA as a cause of CS. Beuschlein et al. () performed WES in  paired adrenal tumor and germline DNA samples from patients with CS, which revealed the presence of a recurrent somatic p.LeuArg mutation in the PRKACA gene in seven cases, with an additional p.Leu_CysinsTrp mutation in one case (). Sequencing of  additional samples identified the p.LeuArg mutation in  of  CPAs (%) from patients with overt CS but not in tumors from  patients with subclinical hypercortisolism (sCS),  APAs,  nonfunctioning adenomas, or  cases of adrenocortical carcinoma (ACC). Among the patients with different forms of BAH leading to CS, including bilateral micro-or macronodular hyperplasia, a germline copy-number gain (duplication) of the genomic region on chromosome  that includes Figure 2 . The two current models for APA development. (Left) Two hit model of APA development. In ZG cells, activation of specific signaling pathways, such as b-catenin, lead to abnormal cell proliferation. Abnormal cell proliferation creates a propitious environment for the occurrence of recurrent somatic mutations specifying the pattern of hormonal secretion. (Right) APCC hypothesis. In ZG cells, the occurrence of somatic mutations in a certain number of APA driver genes leads to the formation of APCCs with autonomous aldosterone production. In a certain number of cases, these structures would evolve toward an APA via a pAATL (83) .
PRKACA was identified in five patients from four kindreds. In one family with bilateral macronodular hyperplasia, the genetic defect was transmitted in an autosomal dominant manner from the mother to her affected child. The p.LeuArg mutation is located in the highly conserved core of the interaction between the regulatory (RIIb) and catalytic (Ca) subunits of PKA. In vitro studies demonstrated gain-of-function of the PKA catalytic subunit mutants with impaired inhibition by the PKA regulatory subunit and increased protein expression of the PKA catalytic subunit in cells from patients with germline chromosomal gains, with both mechanisms leading to increased PKA activity. Basal PKA activity in cells transfected with mutant Ca subunits was increased and was not reduced by excess nonmutant RIIb subunit expression, nor was it responsive to cAMP analogs, indicating that the mutations made the catalytic subunit resistant to physiological suppression. The presence of PRKACA mutations was associated with a more severe phenotype in patients with overt CS and PRKACA mutation carriers had significantly increased expression of MCR, StAR, CYPA, HSDB, and CYPA messenger RNA in adrenal tumors. These results were confirmed in three other studies. By performing WES in  tumor samples producing excess cortisol, including  CPAs and  ACC cases, Goh et al. () identified six cases carrying the recurrent p.LeuArg substitution. Six cases had gain-of-function mutations in CTNNB and two cases in GNAS (coding for Gas), with PRKACA, GNAS, and CTNNB mutations being mutually exclusive. Additional targeted sequencing in  patients identified the p.LeuArg substitution collectively in  of  tumors, representing % of all ACAs and % of all ACAs associated with overt CS. In their study, adenomas carrying PRKACA or GNAS mutations were significantly smaller than those without these mutations, and the patients were younger at diagnosis of overt CS (). WES also revealed a group of tumors harboring many somatic copy number variants, with frequent deletion of CDC and CDKNA, amplification of q., and proteinaltering mutations in TP and RB. This mutational spectrum is more similar to that of malignant tumors, indicating that they might have greater malignant potential or represent early steps toward the development of ACC.
A greater rate of somatic PRKACA mutations seems to occur in subjects with an Asian ancestry. Cao et al. () reported the occurrence of the p.LeuArg mutation (equivalent to the p.LeuArg mutation in the other reports) in .% of a total of  CPAs from China screened by WES and targeted sequencing. In their study, no substantial correlation was found between the mutation status and clinical or biological parameters. The investigators also identified one somatic PRKARA mutation, one CTNNB mutation, a truncating APC mutation, and two activating GNAS mutations in CPA (). An additional CTNNB mutation was found in an adrenal oncocytoma (a very rare form of a cortisol-producing adrenal tumor). The investigators also identified the recurrently mutated gene DOTL coding for a histone H methyltransferase and one HDAC mutation in ACTH-independent macronodular adrenocortical hyperplasia, suggesting involvement of chromatin deregulation, and CLASP mutations in two of three adrenocortical oncocytomas. RNA-sequencing data comparing PRKACA-mutated and -nonmutated tumors identified  differentially expressed genes, with substantial enrichment of gene ontology terms "biosynthesis and metabolism of steroid and cholesterol" and "response to chemical stimulus," with increased expression of the genes StAR, MCR, GSTA, CXCL, and SA/.
Finally, in a Japanese cohort, % of cases (four of eight) with adrenocortical adenomas associated with corticotrophin-independent CS were carriers of the PRKACA p.LeuArg mutation (). An additional patient carried a recurrent p.ArgCys GNAS mutation. Follow-up sequencing in an additional  cases identified the PRKACA p.LeuArg mutation in  cases and GNAS mutation in  cases, representing a total of .% and .% of mutational events and which were mutually exclusive. These mutations were found in % of patients with overt CS, and two patients with sCS were also carriers of a PRKACA and a GNAS mutation. In their study, not only carriers of the recurrent PRKACA p.LeuArg mutation, but also those with GNAS mutations had higher cortisol levels after an overnight dexamethasone suppression test and smaller adenoma size, suggesting greater cortisol output compared with that of nonmutated tumors.
After these seminal studies, a similar prevalence of PRKACA mutations was found in different cohorts of patients with CS from different countries ( Table ) . The largest study published to date was performed within the European Network for the Study of Adrenal Tumors and included  samples from nine different European centers, among which were  CPAs from patients with overt CS,  CPA samples from patients with sCS,  nonsecreting adenomas,  androgen-producing tumors,  ACC cases, and  samples from PBMAH. Heterozygous somatic PRKACA mutations were found in  of  samples from patients with overt CS (%);  patients carried the recurrent p.LeuArg mutation, and a p.Cys_GlyinsVal mutation was identified in three patients and a p.SerArg+p.Leu_LysinsIle-Ile-Leu-Arg mutation was identified in one patient. These newly identified mutations involved a region implicated in the interaction between the PKA regulatory and catalytic subunits. Just as in previous studies, patients with PRKACA mutations showed more severe cortisol abnormalities (greater levels of cortisol after an overnight dexamethasone suppression test) and smaller adenoma size compared with noncarriers (, ). In a study exploring  patients with overt CS (n = ) or sCS (n = ), Thiel et al. () identified the recurrent somatic PRKACA p.LeuArg mutation in .% of tumors, somatic CTNNB mutations (p.SerPro, p.SerPhe) in .%, the recurrent GNAS p.ArgCys mutation in .%, and a double mutation of CTNNB and GNAS in one case. PRKACA and GNAS mutations were again mutually exclusive. In one patient with unilateral hyperplasia, a somatic PRKACA p.LeuArg mutation was identified, and patients with bilateral adenomas did not have known somatic mutations. The presence of PRKACA mutations was associated with younger age, overt CS, and greater cortisol levels after an overnight dexamethasone suppression test compared with non-PRKACA-mutant or CTNNB-mutant lesions (). Finally, targeted genetic screening for GNAS, PRKACA, and KCNJ mutations in Japanese patients,  with CS,  with sCS, and  with an APA found mutations in the PRKACA gene in four patients (%) with CS, and mutations in the GNAS gene were detected in two patients (%). A mutation in the GNAS gene was detected in one patient with sCS (, ).
Altogether, . patients with a CPA or hyperplasia have been investigated. Somatic PRKACA mutations were found in %, CTNNB mutations in %, and GNAS mutations in % of cases (Table ) . PRKACA mutations were associated with overt CS, more severe cortisol abnormalities, and smaller tumors. The question of whether other recurrent mutations or genetic abnormalities are found in CPAs has been addressed by Ronchi et al. () , who performed WES in  patients with ACAs, including  CPAs and  nonfunctioning adenomas negative for PRKACA mutations. Different mutations affecting genes of the cAMP/PKA and Wnt/b-catenin signaling pathways were identified [ Fig. (B) and (C)], the latter are more frequently associated with larger tumors and endocrine inactivity. Genetic variants were also identified in genes belonging to the calcium signaling pathway. To what extent these single variants are causative for cortisol production and/or adenoma formation remains to be established.
Genetics of Aldosterone and Cortisol Cosecretion
Cosecretion of aldosterone and cortisol has been described in several reports, and biochemical abnormalities of cortisol excess in PA have been associated with worse cardiovascular outcomes compared with APAs without cortisol secretion (). Recent studies have suggested that cortisol excess might be more frequent in patients with APAs than previously thought. Histological examination of adrenal glands with APA has consistently shown coexpression of CYPB and CYPB in a number of cases ().
A Japanese study explored somatic GNAS, PRKACA, and KCNJ mutations in  patients with CS,  patients with sCS, and  patients with APAs (, ) ( Table ) . From  APAs tested,  had autonomous cortisol secretion found from an overnight dexamethasone suppression test, increased midnight cortisol levels, and/or decreased plasma ACTH levels. Mutations in the PRKACA gene were found in four patients (%) with CS, and mutations in the GNAS gene were detected in two (%). Mutations in the GNAS gene were also detected in one patient (%) with sCS. Twenty-four patients with APA (%) harbored KCNJ mutations. Among the patients with APA with autonomous cortisol secretion, six carried a somatic KCNJ mutation and two had a somatic GNAS mutation. The KCNJ and GNAS mutations in APA were mutually exclusive. No PRKACA mutations were identified in patients with APA (). In another study, the same investigators identified a KCNJ mutation in two of three patients with APAs and sCS (). In a study of  patients with cortisol excess, Thiel et al. () identified four cases with aldosterone cosecretion,  with overt CS and  with sCS. Among those, two were carriers of mutations in KCNJ (). A distinct histopathological entity is the adrenal harboring two nodules, each one secreting a different hormone. Fallo et al. () investigated the occurrence of concurrent PA and subclinical cortisol hypersecretion in a prospective series of  consecutive patients with PA. In  of the  patients, an overnight dexamethasone suppression test failed to appropriately suppress cortisol. One of these patients also had suppressed ACTH levels and mildly elevated urinary cortisol excretion. The resected adrenal gland showed a -cm nodule expressing CYPB by in situ hybridization. In contrast, CYPB expression was restricted to the peritumoral region composed of ZG-like cells, suggesting the coexistence of a CPA and aldosterone-producing hyperplasia in the same adrenal gland. Nanba et al. () described one patient with lateralized PA and CS, in whom examination of the adrenal gland revealed two distinct nodules, one expressing CYPB and carrying a p.LeuArg PRKACA mutation and one expressing CYPB and carrying a somatic KCNJ mutation.
Altogether, these studies have raised a certain number of questions regarding the histological, cellular, and genetic nature of adrenal lesions producing aldosterone and cortisol. In particular, they emphasize the need to explore the common pathways leading to APA and CPA in terms of signals triggering cell proliferation and/or defining hormonal output.
Common Hits for APA and CPA
Role of the Wnt/b-catenin pathway in adrenal tumorigenesis
The role of the Wnt/b-catenin pathway has emerged as crucial in adrenal development and disease. b-Catenin and ARMC (armadillo repeat-containing protein ; see the section "ARMC mutations in adrenocortical tumors") are both members of the Armadillo repeat containing (ARMC) gene family. Armadillo repeats are approximately  amino acidlong tandemly repeated domains that usually fold together to form a single, rigid protein domain termed the armadillo domain. b-Catenin is a key downstream component of the canonical Wnt signaling pathway. In the absence of Wnt ligand, b-catenin is in complex with AXIN, AXIN, APC, CSNKA, and GSKB, which promotes its phosphorylation on N-terminal Ser and Thr residues, ubiquitination, and subsequent degradation by the proteasome. In the presence of Wnt ligand, the complex is disrupted, and b-catenin GNAS mutations 2 Not described 0 Not described Not described PRKACA mutations 0 a Not described 0 2 Not described CTNNB1 mutations Not described Not described 0 Not described 0 APC mutations Not described Not described Not described Not described 1 (germline)
a In another report, the same investigators reported on the analysis of 33 APAs, 11 with sCS, with none carrying a PRKACA mutation (96) ; however, the overlap between these patients and those from Nakajima et al. (93) is unclear.
accumulates in the nucleus, where it acts as a coactivator for transcription factors of the TCF/ LEF family, leading to transcriptional regulation of Wnt-responsive genes.
Modulation of different components of the Wnt/ b-catenin pathway in mice leads to adrenal abnormalities. In the absence of Wnt, one of the main ligands of the Wnt/b-catenin pathway, mice die immediately after birth of organ defects such as kidney dysfunction or poor pituitary gland development. Despite normal adrenal morphology, Wnt knockout animals produce less aldosterone owing to decreased expression of cypb and show reduced expression of other markers of ZG cells, suggesting a defect in ZG development in the absence of Wnt (). Just as observed in mice, loss of function mutations of WNT in humans leads to dysgenesis of the kidneys and to female and male sex reversal. Adrenal development and external genitalia are also affected in human fetuses (). Along the same lines, the targeted disruption of b-catenin restricted to steroidogenic factor -expressing cells (adrenal cortex, somatic cells of the gonads, spleen, pituitary gonadotropes, and ventromedial hypothalamic nucleus () leads to complete adrenal aplasia when b-catenin is totally absent during development and to a defect in the maintenance of adrenocortical tissue due to increased apoptosis in adult mice when the level of expressed b-catenin is low (). In HR cells, a human adrenocortical cell line with activating CTNNB mutations, a decrease in b-catenin expression induces cell cycle arrest, changes in cell morphology, modification of the expression of epithelial to mesenchymal transition markers, and modification of cell motility (). Although these results highlight the central role of b-catenin in adrenal development, tight regulation of its activation is also crucial. Mice carrying a heterozygous mutation of APC, leading to the formation of a truncated protein and constitutive b-catenin activation, exhibit multiple intestinal tumors. In addition, these mice develop hyperaldosteronism, hypervolemia, and increased blood pressure; however, their adrenal phenotype has not been explored (, ). Mice expressing a constitutively active b-catenin in the adrenal cortex exhibit progressive adrenal hyperplasia and dysplasia, leading, with time, to the formation of nodules in both cortex and medulla. Abnormal vascularization was also observed and, in later stages in rare cases, the development of adrenal carcinoma (). In humans, activation of b-catenin, demonstrated by its cytoplasmic and/or nuclear accumulation, was found in a large number of adrenocortical tumors, including adrenocortical adenomas (, -). Mutations in the CTNNB gene, leading to constitutive activation of b-catenin, were found in both malignant and benign tumors [ Fig. (C)] (, ) . In benign tumors, the presence of b-catenin mutations was associated with larger adenomas and the absence of hormonal secretion (). In hormonally active ACA, the prevalence of CTNNB mutations has been estimated at % to % in APAs (, , ) and~% in CPA (see previous sections). The presence of CTNNB mutations in APAs was not associated with a particular histological or morphological phenotype but seems to be more prevalent in females (, , , ). In addition, Teo et al. () reported the cases of three women with PA with CTNNB mutations in their adenoma that were associated with aberrant expression of G protein-coupled receptors, two during pregnancy and one after menopause, suggesting a possible acceleration of the disease during pregnancy and menopause due to high gonadotropin levels acting on aberrantly expressed gonadotropin receptors. Because CTNNB mutations were also reported in nonpregnant women (, ) and men, the relation between CTNNB mutations and pregnancy and the possible interaction with aberrant gonadotropin receptors remain to be further clarified (, ).
The role of the Wnt/b-catenin pathway in the development of APA is further supported by the case of a young patient in whom severe arterial hypertension due to primary aldosteronism was diagnosed at age , followed by hemorrhagic stroke  years later owing to lateralized aldosterone secretion from an APA in the context of bilateral multinodular adrenal glands (). The patient, in whom additional exploration identified asymptomatic familial adenomatous polyposis (FAP) associated with a heterozygous germline APC mutation, showed biallelic APC inactivation due to loss of heterozygosity in two adrenal nodules. The aldosterone-producing nodule carried an additional somatic KCNJ mutation supporting a twohit model for APA development (). This patient also had incomplete cortisol suppression after an overnight dexamethasone suppression test but normal -hour urinary free cortisol, maintained circadian rhythm of cortisol secretion, and normal ACTH levels. CYPB expression was detected in all adrenal nodules, including the one carrying the KCNJ mutation (data unpublished).
Remarkably, a link between the Wnt/b-catenin and the PKA pathway has recently been established, showing that activation of PKA prevents ZG differentiation through WNT repression and Wnt pathway inhibition, suggesting that PKA activation in the ZF is a key driver of Wnt inhibition and lineage conversion ().
ARMC5 mutations in adrenocortical tumors
Evidence that ARMC is involved in adrenal tumorigenesis came from recent studies exploring PBMAH (also called ACTH-independent macronodular adrenal hyperplasia or ACTH-independent macronodular adrenocortical hyperplasia). PBMAH is a form of macronodular adrenal hyperplasia characterized by multiple, bilateral, nonpigmented, benign, adrenocortical nodules.
It results in excessive production of cortisol, leading to ACTH-independent overt CS or sCS ().
Germline ARMC mutations were identified in familial cases and are present in % of apparently sporadic cases. Somatic events occur independently in adrenal nodules, suggesting that ARMC acts as a tumor suppressor gene ().
A recent study has shown that PBMAH is not truly ACTH-independent because proopiomelanocortin expression was described in clusters of steroidogenic cells in PBMAH tissue, suggesting local ACTH production with paracrine regulation of cortisol biosynthesis (). The existence of heterogeneous phenotypes (), such as that observed in a Brazilian family with adrenal macronodular disease showing bilateral and unilateral adrenal nodules, has highlighted the complexity of the condition, leading some investigators to prefer the name primary macronodular adrenal hyperplasia (). PBMAH is usually diagnosed after the investigation of an adrenal incidentaloma or by the presence of overt CS, although insidious or mild CS has been more frequent (, ). Aldosterone secretion was also described in patients with PBMAH (, , ). Previous studies have demonstrated that cortisol secretion in PBMAH might be regulated by various hormones via aberrant adrenal expression of several G protein-coupled receptors (, , ). Illegitimate G protein-coupled receptors expressed in PBMAH include the gastric inhibitory polypeptide receptor, vasopressin receptors, badrenergic receptors, luteinizing hormone/human chorionic gonadotropin receptors, and the serotonin -HT and -HT receptors ().
Although sporadic forms appear to be more frequent, the description of familial forms and the occurrence of bilateral adrenal lesions support a genetic cause for PBMAH. Recently, combined single nucleotide polymorphism array and microsatellite marker analysis have shown a somatic p loss of heterozygosity (LOH) in  of  tumor samples from patients with PBMAH. In parallel, WES analysis, followed by direct sequencing of blood and tumor samples, has identified somatic mutations in ARMC, the armadillo repeat-containing  gene mapped to p., in  of  PBMAH patients (). All patients carried a germline ARMC mutation and a second somatic ARMC event in the tumor DNA, including LOH, a second mutation, or microdeletion, suggesting a -hit model for the development of PBMAH (). Distinct somatic ARMC alterations have been observed in different nodules from the same adrenal gland (), exemplified by an emblematic case of  different somatic ARMC mutations in  adrenal nodules from the same patient ().
The function of ARMC is unknown, and no other diseases have been associated with mutations in this gene. ARMC encodes a -amino acid protein of the armadillo repeat family containing an armadillo repeat domain in the N-terminal region and a BTB/POZ in the C-terminal region (). Analysis of the expression of four ARMC isoforms in  human tissues has shown that at least one ARMC isoform is ubiquitously expressed throughout the body, but only seven tissues expressed all four isoforms, including the adrenal gland (). Armc knockout mice have defective development and immune responses, with adrenal hyperplasia in old animals (). Transfection of wildtype ARMC in HR cells induces apoptosis, which is not observed when mutant ARMC cells are transfected. Furthermore, silencing of ARMC in HR cells reduced the expression of the steroid enzymes CYPA, CYPA, NRA, and MCR and cortisol production (). Patients with PBMAH and ARMC mutations experience a greater incidence of overt CS than patients with PBMAH without ARMC mutations (, ). In a cohort of  unrelated subjects with PBMAH, ARMC mutations were found in  patients (%). Patients with ARMC mutations again more frequently showed overt CS and had larger adrenal glands with a greater number of nodules than did patients without mutations (). These results were confirmed in an Italian cohort of patients with PBMAH, in which patients with ARMC mutations exhibited greater cortisol levels, more severe hypertension, diabetes, and larger adrenal lesions (). ARMC mutations have also been identified in familial forms of PBMAH (, -). In one Brazilian family with PBMAH, a germline ARMC mutation was found that segregated with the disease, although the clinical phenotype and adrenal involvement (unilateral or bilateral) were variable among carriers (). In five families with PBMAH, Gagliardi et al. () have found germline ARMC mutations in four families with CS and no ARMC mutation in one family with PA and sCS. In a large French-Canadian PBMAH family, ARMC mutations were found in affected subjects, together with aberrant expression of b-adrenergic and V-vasopressin receptors in adrenal nodules (). Thus, the aberrant expression of G protein-coupled receptors might represent a secondary event in the development of PBMAH; however, the link between ARMC mutations and this pattern of receptor expression has not yet been clarified.
Zilbermint et al. () sequenced ARMC in germline DNA from  subjects with PA and identified  heterozygous variants,  missense variants, and  variants leading to alternative splicing. In silico analysis of the ARMC variants has shown that six variants were predicted to be damaging, including the ARMC variant p.RW, which was previously described in one patient with PBMAH () and a novel missense mutation ARMC p.PH (). All carriers of these variants were African American, two had bilateral macronodular hyperplasia, and tumor DNA sequencing showed neither additional somatic "The functional consequences of these ARMC 5 $ variants are not completely understood."
ARMC mutations nor ARMC loss of heterozygosity. APAs with predicted damaging ARMC variants exhibit lower ARMC expression than the adjacent adrenal cortex. The functional consequences of these ARMC variants are not completely understood. Silencing of ARMC in HR cells leads to decreased CYPB expression and, therefore, a reduction of the aldosterone-secretory capacity. The investigators suggested that the greater aldosterone secretion in patients with PA carrying ARMC variants might be explained by the increased adrenocortical mass, similar to that observed in patients with PBMAH and hypercortisolism (). An association of ARMC mutations with PA was not replicated in an Italian study assessing the presence of ARMC mutations in  patients with PA and bilateral computed tomography-detected adrenal alterations, from which  had unilateral and  bilateral aldosterone secretion (). Different ARMC variants were identified in  subjects, including  common variants,  rare variants, and  previously unreported variants. However, in silico analysis did not identify possibly damaging ARMC variants (). These contradictory data do not allow confirmation of the role of ARMC mutations in PA, and further studies are required to better understand the role of ARMC in the development of adrenal nodules and aldosterone excess. . FAP is a disease characterized by multiple colonic polyps with an increased risk of colon carcinoma, owing to an inactivating germline mutation of APC and a somatic second hit (mutation or LOH), resulting in constitutive activation of the Wnt/b-catenin pathway (). Adrenal masses are more frequently found in patients with FAP than in the general population (), including nonfunctioning adrenal adenomas, adrenocortical cancers, and PBMAH (, ). Multiple endocrine neoplasia type  (MEN) is an autosomal dominant syndrome resulting from inactivating mutations in the MEN gene, which is characterized by the development of multiple endocrine and nonendocrine tumors, most frequently hyperparathyroidism, pituitary adenoma, and pancreatic neuroendocrine tumors (). MEN encodes the protein menin, which has a role in the regulation of cell cycle, cell growth, and proliferation (). The analysis of adrenal involvement in  patients with MEN has shown adrenal tumors (. mm in size) in % of the cohort (). In .% of these cases, the tumors were bilateral, and in .% of the cases, the tumors were . mm (). A MEN mutation was also identified in one patient with PBMAH and hyperparathyroidism, without a family history or other endocrine abnormalities (). In addition, LOH at the MEN locus was also reported in APAs (). Another hereditary disease associated with PBMAH is the hereditary leiomyomatosis and renal cell carcinoma syndrome (HLRCC), a disease caused by germline mutations in the fumarate hydratase gene (). Adrenal lesions are found in .% of patients with HLRCC, including bilateral lesions associated with ACTH-independent hypercortisolism (), and germline fumarate hydratase mutations were identified in patients with PBMAH associated with HLRCC (, ). Genetic alterations leading to activation of cAMP/PKA signaling were also described in patients with PBMAH. Postzygotic somatic mutations in the gene encoding the a subunit of stimulatory G protein (GNAS), leading to constitutive activation of adenylate cyclase, result in McCune-Albright syndrome, which is characterized by a triad constituted by polyostotic fibrous dysplasia, café au lait skin spots, and gonadotrophinindependent precocious puberty, associated with other endocrine and nonendocrine diseases, including CS (). Somatic GNAS mutations were described in a few cases of PBMAH without other typical signs of McCune-Albright syndrome and might represent variants of this syndrome (, ). In isolated cases, variants in PDEA, encoding the isoform A of the phosphodiesterase enzyme, and in MCR were associated with PBMAH (-). Finally, duplication of a genomic region of chromosome , including PRKACA, was also identified in patients with PBMAH (, ).
Conclusion
During the past few years, extraordinary progress has been made in our understanding of the genetic abnormalities leading to APAs and CPAs. Although genetic testing in inherited forms of the diseases has been translated into clinical practice, and family screening is useful for the management of affected family members, the clinical utility of diagnosing somatic mutations is difficult to anticipate from available studies on genotype-phenotype correlations and outcome. Ideally, identification of mutations before surgery, through application of surrogate biomarkers or genetic testing on circulating cell-free DNA, could guide treatments to specifically target mutated proteins, such as was shown for APAs (, ). An overlap seems to exist of genetic abnormalities leading to different endocrine abnormalities in ACA. In particular, CTNNB mutations are found at a relatively high frequency (at least comparable to that observed for ATPA or ATPB mutations in APA) in CPA but also usually in APA. Furthermore, genetic variants affecting genes of the calcium signaling pathway are enriched in WES data from CPA, suggesting that calcium, in addition to PKA signaling, might lead to autonomous cortisol overproduction. This is not surprising, because a subset of APAs shows some cortisol cosecretion or biochemical glucocorticoid abnormalities (). In some cases, those tumors harbor somatic KCNJ mutations. In addition, overexpression of mutated GIRK channels in HAC cells not only increases CYPB expression but also increases CYPB (). Future studies should address the sequence of events leading to adrenal cell proliferation, nodule formation, and specification of the hormonal secretory pattern. It will be of particular interest to explore whether common susceptibility alleles or rare variants might predispose to the development of APAs and CPAs.
